, Volume 172, Issue 3, pp 291–297

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

  • Ismene L. Petrakis
  • Stephanie O’Malley
  • Bruce Rounsaville
  • James Poling
  • Colette McHugh-Strong
  • John H. Krystal
  • VA Naltrexone Study Collaboration Group
Original Investigation



Alcohol abuse in patients with schizophrenia is associated with psychiatric and social complications. While two medications have been approved by the Federal Drug Administration (FDA) for the treatment of alcoholism: disulfiram and naltrexone, no medications have been approved for individuals with alcohol dependence and comorbid schizophrenia. The purpose of this study was to evaluate the efficacy of naltrexone in alcohol-abusing schizophrenic patients.


Thirty-one patients with schizophrenia and comorbid alcohol abuse or dependence were treated for 12 weeks in an outpatient study using naltrexone or placebo in a randomized, double-blind fashion in addition to their neuroleptic medication. Patients also participated in a weekly therapy using cognitive-behavioral drug relapse prevention strategies combined with skills training. Outcomes included drinking measured by the time line follow-back method, craving using the Tiffany Craving Questionnaire, psychotic symptoms using the Positive and Negative Symptoms Scale (PANSS), side effects and a measures of abnormal involuntary movements.


There were no significant differences in treatment exposure or medication compliance between groups. Naltrexone treated patients had significantly fewer drinking days, heavy drinking days (>5 drinks) and reported less craving compared to the placebo treated patients. Naltrexone did not affect symptoms of schizophrenia, such as psychosis. The medication was well tolerated and there were no group differences in side effects.


These data suggest that naltrexone may be an effective medication for individuals with comorbid alcohol dependence and schizophrenia. Given the widespread problems associated with alcohol misuse in this population, and the lack of effective pharmacotherapies, these findings represent an exciting clinical development.


Naltrexone Alcohol Schizophrenia Comorbidity Dual diagnosis 


  1. Batki S, Dimmock J, Cornell M, Wade M, Carey K, Maisto, S (2002) Directly observed naltrexone treatment of alcohol dependence in schizophrenia: preliminary analysis. Alcohol Clin Exp Res 26:83AGoogle Scholar
  2. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 54:1130–1135PubMedGoogle Scholar
  3. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732–739PubMedGoogle Scholar
  4. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L (1974) The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 19:1–15PubMedGoogle Scholar
  5. Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 35:S93–100CrossRefGoogle Scholar
  6. Drake RE, Xie H, McHugo GJ, Green AI (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441–449PubMedGoogle Scholar
  7. Gerding LB, Labbate LA, Measom MO, Santos AB, Arana GW (1999) Alcohol dependence and hospitalization in schizophrenia. Schizophr Res 38:71–75CrossRefPubMedGoogle Scholar
  8. Guy W (1976) ECDEU assessment manual for psychopharmacology. Publication 76-338, Washington D.C.Google Scholar
  9. Hansen L, Larsen N (1982) Metabolic interaction between perphenazine and disulfiram. Lancet 2:1472CrossRefGoogle Scholar
  10. Hedeker D, Gibbons R, Davis J (1991) Random regression models for multicenter clinical trials data. Psychopharmacol Bull 27:73–77PubMedGoogle Scholar
  11. Kavanagh D, McGrath J, Saunders J, Dore G, Clark D (2002) Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62:743–755PubMedGoogle Scholar
  12. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMedGoogle Scholar
  13. Koob GF (2000) Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 909:170–185PubMedGoogle Scholar
  14. Kranzler H, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335–1341Google Scholar
  15. Krystal J, Cramer J, Krol W, Kirk G, Rosenheck R (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734–1739CrossRefPubMedGoogle Scholar
  16. Marra D, Warot D, Berlin I, Hispard E, Notides C, Tilikete S, Payan C, Lepine J, Dally S, Aubin H (2002) Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 26:1545–1552PubMedGoogle Scholar
  17. Maxwell S, Shinderman MS (2000) Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 19:61–69Google Scholar
  18. Mueser K, Noordsy DL, Fox L, Wolfe R (2003) Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12:242–252PubMedGoogle Scholar
  19. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881–887PubMedGoogle Scholar
  20. O’Malley SS, JA, Rode S, Rounsaville BJ (1996) Experience of a “slip” among alcoholics treated with naltexone or placebo. Am J Psychiatry 153:281–283PubMedGoogle Scholar
  21. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacologia 160:19–29CrossRefGoogle Scholar
  22. Petrakis I, Trevisan L, D’Souza DC, Gil R, Krasnicki S, Boutros N, Cooney N, Krystal JH (1999) CSF monoamine metabolite and beta-endorphin levels in recently detoxified alcoholics and healthy controls: prediction of alcohol cue-induced craving. Alcohol Clin Exp Res 23:1336–1341PubMedGoogle Scholar
  23. Petrakis IL, Trevisan L, Boutros NN, Limoncelli D, Cooney NL, Krystal JH (2001) Effect of tryptophan depletion on alcohol cue-induced craving in abstinent alcoholic patients. Alcohol Clin Exp Res 25:1151–1155PubMedGoogle Scholar
  24. Petrakis IL, Buonopane A, O’Malley SS, Cermik O, Trevisan L, Boutros NN, Limoncelli D, Krystal JH (2002) The effect of tryptophan depletion on alcohol self-administration in non-treatment seeking alcoholic individuals. Alcohol Clin Exp Res 26:969–975PubMedGoogle Scholar
  25. Pickar D, Vartanian F, Bunney WE, Maier HP, Gastpar MT, Prakash R, Sethi BB, Lideman R, Belyaev BS, Tsutsulkovskaja MVA, Jungkunz G, Medopil N, Verhowven W, Praag H (1982) Short-term nalaxone administration in schizophrenic and manic patients. Arch Gen Psychiatry 39:313–319PubMedGoogle Scholar
  26. Pickar D, Bunney W, Douillet P, Sethi B, Sharma M, Vartanian M, Lideman R, Naber D, Leibl K, Yamashita I, Koyama T, Verhoven W, Vartanian F, Morozov P, Khac T (1989) Repeated naloxone administration in schizophrenia: a phase II World Health Organization study. Biol Psychiatry 25:440–448CrossRefPubMedGoogle Scholar
  27. Project Match Research Group (1997) Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes. J Stud Alcohol 58:7–29PubMedGoogle Scholar
  28. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study [see comments]. JAMA 264: 2511–2518PubMedGoogle Scholar
  29. Roberts L, Shaner A, Eckman T (1999) Overcoming addictions: skills training people for people with schizophrenia. W.W. Morton & Company, New YorkGoogle Scholar
  30. Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C (1998) Naltrexone utility in depressed alcoholics. Psychopharmacol Bull 34:111–115PubMedGoogle Scholar
  31. Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL, Krystal JH, Price LH (1998) Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 18:248–251CrossRefPubMedGoogle Scholar
  32. Shaw G, Majumdar S, Waller S, MacGarvie J, Dunn G (1987) Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 150:164–168PubMedGoogle Scholar
  33. Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (eds) Measuring alcohol consumption. Humana Press, Clifton, N.J.Google Scholar
  34. Spitzer RL, Williams JB, Gibbon M, First MB (1992) The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49:624–629PubMedGoogle Scholar
  35. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463–1467PubMedGoogle Scholar
  36. Tiffany ST, Singleton E, Haertzen CA, Henningfield JE (1993) The development of cocaine craving questionnaire. Drug Alcohol Depend 34:19–28PubMedGoogle Scholar
  37. Volpicelli JR, Alterman A, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876–880PubMedGoogle Scholar
  38. Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP (1995) Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry 152:613–615PubMedGoogle Scholar
  39. Wiesbeck G, Weijers H, Lesch O, Glasser T, Toennes P, Boening J (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol 36:329–334CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Ismene L. Petrakis
    • 1
    • 2
  • Stephanie O’Malley
    • 1
  • Bruce Rounsaville
    • 1
  • James Poling
    • 1
  • Colette McHugh-Strong
    • 1
  • John H. Krystal
    • 1
  • VA Naltrexone Study Collaboration Group
  1. 1.Department of PsychiatryYale UniversityNew HavenUSA
  2. 2.West Haven Veterans Administration Medical Center #116-AWest HavenUSA

Personalised recommendations